Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis

Prostate

Volumn 72, Issue 6, 2012, Pages 626-637

  Endoh, Kanji ^a,b   Nishi, Mayuko ^b   Ishiguro, Hitoshi ^b,c   Uemura, Hiroji ^b   Miyagi, Yohei ^d   Aoki, Ichiro ^b   Hirano, Hisashi ^e   Kubota, Yoshinobu ^b   Ryo, Akihide ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

androgen receptor; prognostic marker; prostate cancer; tumor recurrence

Indexed keywords

ANDROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; GENE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; MICRODISSECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TKR FUSED GENE; TUMOR RECURRENCE; UPREGULATION;

AGED; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PEPTIDYLPROLYL ISOMERASE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEOMICS; RATS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84858745727     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21466     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R,. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163 (3): 806-812. (Pubitemid 30091621)
3. Abate-Shen C, Shen MM,. Molecular genetics of prostate cancer. Genes Dev 2000; 14 (19): 2410-2434.
4. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG,. Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91 (3): 459-477.
5. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW,. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57 (6): 1033-1037. (Pubitemid 32455561)
6. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, Chambers TC,. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008; 283 (51): 35517-35525.
7. Kirkland PA, Humbard MA, Daniels CJ, Maupin-Furlow JA,. Shotgun proteomics of the haloarchaeon Haloferax volcanii. J Proteome Res 2008; 7 (11): 5033-5039.
8. Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider MH, Van Den Neste E, Bontemps F,. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006; 281 (8): 4887-4893. (Pubitemid 43847750)
9. Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM,. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol 2010; 80 (5): 739-747.
10. Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Zhang X, Tanaka T, Maehara S, Maehara Y, Sakaida I, Nakamura K,. Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 2010 30 (9): 3367-3372.
11. Schutkowski M, Bernhardt A, Zhou XZ, Shen M, Reimer U, Rahfeld JU, Lu KP, Fischer G,. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 1998; 37 (16): 5566-5575. (Pubitemid 28241940)
12. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S, Lu KP,. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12 (6): 1413-1426. (Pubitemid 38037011)
13. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM,. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 2008; 7: 91.
14. Ryo A, Liou YC, Lu KP, Wulf G,. Prolyl isomerase Pin1: A catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 2003; 116 (Pt 5): 773-783. (Pubitemid 36367627)
15. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F,. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 285 (3): 1754-1764.
16. Cooke DB, Quarmby VE, Petrusz P, Mickey DD, Der CJ, Isaacs JT, French FS,. Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. Prostate 1988; 13 (4): 273-287. (Pubitemid 19057298)
17. Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, Yamamoto N,. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 2009; 5 (12): e1000700.
18. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I,. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177 (2): 540-545. (Pubitemid 46054056)
19. Greene FL, Sobin LH,. A worldwide approach to the TNM staging system: Collaborative efforts of the AJCC and UICC. J Surg Oncol 2009; 99 (5): 269-272.
20. Ryo A, Uemura H, Ishiguro H, Saitoh T, Yamaguchi A, Perrem K, Kubota Y, Lu KP, Aoki I,. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 2005; 11 (20): 7523-7531. (Pubitemid 41507714)
21. Miranda C, Roccato E, Raho G, Pagliardini S, Pierotti MA, Greco A,. The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway. J Cell Physiol 2006; 208 (1): 154-160. (Pubitemid 43849000)
22. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, Wheeler TM, Lu KP, Bao L,. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003; 63 (19): 6244-6251. (Pubitemid 37255170)
23. Sasaki T, Ryo A, Uemura H, Ishiguro H, Inayama Y, Yamanaka S, Kubota Y, Nagashima Y, Harada M, Aoki I,. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract 2006; 202 (5): 357-364.
24. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P,. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84 (15): 5277-5281. (Pubitemid 17129009)
25. Xu X, Fu XY, Plate J, Chong AS,. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58 (13): 2832-2837. (Pubitemid 28311915)